Psoriasis patients exposed to high cumulative doses of psoralen þ ultraviolet A frequently exhibit so-called ''psoralen þ ultraviolet A keratoses'' (i.e., hyperkeratotic lesions with varying degrees of histologic atypia). The exact causes and molecular mechanisms of psoralen þ ultraviolet A keratoses however, are not clear. We therefore performed DNA mutational analysis of the tumor suppressor gene p53 (exons in psoralen þ ultraviolet A keratoses from 10 long-term psoralen þ ultraviolet A-treated psoriasis patients. We detected 39 p53 mutations in 16 of 28 psoralen þ ultraviolet A keratoses (57%) and 18 Ha-ras mutations in 11 of 25 psoralen þ ultraviolet A keratoses (44%). Of the 39 p53 mutations and 18 Ha-ras mutations, 22 (56%) and 13 (72%), respectively, were of the ultraviolet fingerprint type (C ! T or CC ! TT transitions at dipyrimidine sites); 13 (33%) and two (11%), respectively, occurred at potential psoralen-binding sites (5 0 -TpA, 5 0 -TpG, or 5 0 -TpT DNA sequences) and were potentially psoralen þ ultraviolet A induced; two (5%) and three (17%), respectively, were of ambiguous origin (ultraviolet and/ or psoralen þ ultraviolet A); and two (5%) and none (0%), respectively, were of the ''other'' type, respectively. We conclude that (1) the frequent mutation of p53 and Ha-ras may play a key part in the formation of at least some psoralen þ ultraviolet A keratoses; (2) environmental and/or therapeutic ultraviolet exposure may be a major cause of psoralen þ ultraviolet A keratosis as most Ha-ras and p53 mutations are induced by ultraviolet light; and (3) psoralen þ ultraviolet A itself plays a smaller, though direct, role in causing these mutations.
Psoriasis patients exposed to high cumulative doses of psoralen þ UVA (PUVA) are at increased risk of skin cancer, particularly squamous cell carcinoma (SCC) (for review see Stern et al, 1998) . Long-term PUVA-treated psoriasis patients also frequently exhibit squamous keratoses that show varying degrees of histologic dysplasia (Abel et al, 1982; Gupta et al, 1990; Bruynzeel et al, 1991; Van Praag et al, 1993; Lever and Farr, 1994; Buckley and Rogers, 1996; Hudson-Peacock et al, 1996) . These so-called ''PUVA keratoses'' appear on PUVA-treated body sites. They have been described as papules, ranging in diameter from several millimeters to about 1 cm, that have a broad base and hyperkeratotic, scaly, warty-appearing top (Van Praag et al, 1993) . Histologically, PUVA keratoses exhibit acanthosis; orthokeratosis; focal parakeratosis; some apoptotic cells in the epidermis; and often some mild, perivascular, predominantly lymphocytic infiltrate in the papillary dermis that slightly invades the epidermis. An estimated 50% of all PUVA keratoses exhibit mildly atypical keratinocytes (Van Praag et al, 1993) .
PUVA keratoses are associated with an increased risk of nonmelanoma skin cancer (Lever and Farr, 1994; Van Praag et al, 1993) . For instance, Van Praag et al (1993) established that the relative risk for skin cancer is more than 6-fold higher for patients with PUVA keratoses than for psoriasis patients who also received long-term PUVA but do not have these keratoses. They also showed that this holds true even after adjustment for age, sex, and UVA dose. It is still not known for certain, however, whether PUVA keratoses are direct precursors of SCC or only indicators of increased risk. Nor are the exact causes and molecular mechanisms of PUVA keratoses yet known. The search for answers is made more difficult by the fact that patients with severe psoriasis often have additional risk factors for skin cancer, including previous exposure to known or suspected carcinogenic agents and treatments such as therapeutic and/or environmental UV radiation, ionizing radiation, methotrexate, cyclosporine, arsenic, or topical tar (for review see Maier et al, 1996; Paul et al, 2003) .
A number of molecular studies have suggested that mutations in the p53 tumor suppressor gene and the Ha-ras proto-oncogene, two of the genes most frequently mutated in cancers, are involved in the formation of PUVAassociated skin cancers. Epidemiologic DNA mutational analyses of these genes have revealed that therapeutic and/ or environmental exposure to UV light is a significant factor Abbreviations: BCC, basal cell carcinoma; MOP, methoxypsoralen; PUVA, psoralen plus UVA; SCC, squamous cell carcinoma; SSCP, single-strand conformation polymorphism.
Copyright r 2003 by The Society for Investigative Dermatology, Inc. in the formation of PUVA-associated SCC and basal cell carcinomas (BCC) (Nataraj et al, 1997; Wang et al, 1997; Kreimer-Erlacher et al, 2001; Seidl et al, 2001; Stern et al, 2002) . DNA sequencing analysis of the two genes in skin cancers from PUVA-treated psoriasis patients has revealed not only PUVA-induced mutations at psoralen-binding sites (i.e., at or near 5 0 -TpA, 5 0 -TpG, or 5 0 -TpT sequences) but also mutations bearing the UV fingerprint (i.e., C ! T or CC ! TT transitions at dipyrimidine DNA sequences) (Brash et al, 1991; Rady et al, 1992; Campbell et al, 1993; Kanjilal et al, 1993; Moles et al, 1993; Ziegler et al, 1993 Ziegler et al, , 1994 Nakazawa et al, 1994; Nelson et al, 1994; Taguchi et al, 1994; Park et al, 1996; Nomura et al, 1997) .
In this light, we hypothesized that mutations in the p53 and Ha-ras genes may cause PUVA keratoses that are predisposed to become skin cancers. To prove this, we subjected PUVA keratoses obtained from patients at the Department of Dermatology, Karl-Franzens University (Graz, Austria) to DNA mutational analysis of their p53 and Ha-ras genes in the hope of identifying potential causative factors and determining the relation, if any, between the formation of these keratoses and the formation of skin cancers.
Results
UV fingerprint mutations occurred frequently in the p53 and Ha-ras genes of PUVA keratoses A total of 39 p53 mutations (35 mis-sense and four non-sense) were found in 16 of 28 PUVA keratoses (57%) from nine of 10 patients (90%) ( Table II) . Of those 39 p53 mutations, 31 (79%) occurred at dipyrimidine sites, and 24 (62%) were of the UV type (23 C ! T transitions and one CC ! TT transition). Two of the C ! T transitions occurred at dipyrimidine sites opposite a 5 0 TpG sequence (a potential psoralen-binding site) (codon 322 in lesion A1 and codon 136 in lesion D1). As this made the origin of these mutations (UV or PUVA) ambiguous, they were considered separately in DNA mutational analysis (Fig 1) . In addition, three other mutations (8%) occurred at 5 0 TpG sites (one at a dipyrimidine site and two at nondipyrimidine sites), one (3%) at a 5 0 TpT site, and nine (23%) at 5 0 -TpA sites (six at dipyrimidine sites and three at nondipyrimidine sites); all of these mutations were potentially PUVA induced. In addition, one C ! T transition occurred at a nondipyrimidine site, and one G ! C transversion occurred opposite a dipyrimidine site (when taken together, 5% of all p53 mutations observed in this study). None of the p53 mutations detected in the PUVA keratoses were found in normal skin tissue dissected from the same patients. In all lesional and normal skin tissue samples from patients I and H, however, a G ! C transversion at codon 72 was present; and in all lesional and normal skin tissue samples from patients D and E, an A ! G transition at codon 213 was present. Both of these base changes have been previously described as p53 polymorphisms (Vogel and Kopun, 1977; Cooper and Krawczak, 1993) . In addition, seven silent p53 mutations (four of UV type, two of PUVA type, and one of other type) were found in the PUVA keratoses.
A total of 18 Ha-ras mutations (17 mis-sense and one non-sense) were found in 11 of 25 PUVA keratoses (44%) from six of nine patients (66%) ( Table III) . Thirteen of these 18 mutations (72%) bore the UV fingerprint (C ! T transitions at dipyrimidine sites), two (11%) at a 5 0 -TpG site (a sign of possible PUVA induction), and three (17%) at dipyrimidine sites opposite a 5 0 -TpG sequence (a sign of possible UV and/or PUVA induction). None of the Ha-ras mutations detected in the PUVA keratoses were found in normal skin tissue dissected from the same patients. In all lesional and normal skin tissue samples from seven of nine patients (patients A-F and H) (78%), however, a T:A ! C:G base change at codon 27 was present. This change has previously been described as a silent Ha-ras polymorphism (Chapon et al, 1983; Hsieh et al, 1994; Kreimer-Erlacher et al, 2001) . In addition, 19 silent Ha-ras mutations (12 of UV type, two of PUVA type, two of UV/PUVA type, and three of other type) were found in the PUVA keratoses.
DNA sequencing analysis of both the p53 and the Ha-ras gene was done for 25 of 28 PUVA keratoses; for the other three samples, DNA was exhausted before it could be analyzed for Ha-ras gene (Table IV) . The sequencing data revealed that seven of 25 PUVA keratoses (28%) had both p53 and Ha-ras mutations, seven (28%) had only p53 mutations, four (16%) had only Ha-ras mutations, and seven (28%) had neither mutation.
The UV fingerprint portion of the p53 mutation spectrum in PUVA keratoses was similar to that in actinic keratoses from the general population The p53 mutational spectrum in this study was compared with the p53 mutational spectrum derived from a pool of previous sequencing studies of actinic keratoses from the general population (Fig 1) . PUVA keratoses exhibited a significantly higher percentage of PUVA-type p53 mutations than did the actinic keratoses (13 of 39 (33%) vs eight of 56 (14%); Fisher's exact test, p ¼ 0.043). In addition, PUVA keratoses exhibited a significantly higher percentage of these mutations at 5 0 -TpA sites (nine of 39 (23%) vs one of 56 (2%); Fisher's exact test, p ¼ 0.0012). Conversely, PUVA keratoses exhibited a significantly lower percentage of all mutations of the ''other'' type (three of 39 (8%) vs 16 of 56 (27%); Fisher's exact test, p ¼ 0.031). There was, however, no statistically significant difference between PUVA keratoses and actinic keratoses in terms of the number of UV fingerprint p53 mutations (22 of 39 (56%) vs 27 of 56 (48%); Fisher's exact test, p ¼ 0.431).
Comparison of mutation types in PUVA keratoses and PUVA-associated SCC at p53 and Ha-ras p53 and Ha-ras mutations in PUVA keratoses were compared with those in SCC from PUVA-treated psoriasis patients in terms of type, number, and frequency ( Fig 2) . Regarding p53, PUVAassociated SCC exhibited more PUVA-type mutations and fewer UV-type mutations of the p53 gene than did PUVA keratoses, although these differences did not reach statistical significance (w 2 test; p ¼ 0.07 and p ¼ 0.22, respectively). Regarding Ha-ras, PUVA-associated SCC exhibited significantly fewer UV-type mutations (six of 18 (33%) vs 13 of 18 (72%)) (Fisher's exact test, p ¼ 0.044) and significantly more mutations of the ''other'' type (seven of 18 (39%) vs 0%) (Fisher's exact test, p ¼ 0.007) than did PUVA keratoses. PUVA-associated SCC exhibited more PUVA- Type of mutation
The sequence is shown in 5 0 ! 3 0 direction for the strand (transcribed or nontranscribed) containing the pyrimidine(s) at mutation site. Nucleotides of the affected codon are written in capital letters. Mutated bases are shown in bold letters. Multi-and dipyrimidines with UV-type mutations (C ! T transitions) are underlined once; potential psoralen-binding sites (5 0 -TpA, 5 0 -ApT, 5 0 -TpG/5 0 -CpA, 5 0 -TpT/5 0 -ApA) with mutations (i.e., PUVA-type mutations) are underlined twice. b T, transcribed strand; NT, nontranscribed strand.
type mutations of the Ha-ras gene than did PUVA keratoses, although these differences did not reach statistical significance (Fisher's exact test, p ¼ 0.40).
Discussion
Our sequence analysis study revealed that both the p53 gene and the Ha-ras gene were frequently mutated in PUVA keratoses (Tables II-IV) . Of particular interest were three findings: (1) 56% of p53 mutations (22 of 39) and 72% of Ha-ras mutations (13 of 18) occurred at dipyrimidine sites and bore the UV fingerprint (C ! T or CC ! TT transitions);
(2) 33% of p53 mutations (13 of 39) and 11% of Ha-ras mutations (two of 18) occurred at potential psoralen-binding sites (5 0 -TpA, 5 0 -TpG, or 5 0 -TpT DNA sequences) and were thus potentially PUVA induced; and (3) the mutation spectra of p53 and in particular Ha-ras did not show the typical hotspot region distribution that had been previously reported. For instance, most Ha-ras mutations were found at other sites than the common oncogenic hotspots at codon 12, 13, and 61. Concerning p53, however, more than 70% of the mutations (including the hotspot mutations at codon 248 and 282) detected in this study have been previously reported from other cancers, including cutaneous SCC (data not shown) (http://www.umd.necker.fr/). The findings on mutation types agree with those of p53 sequencing studies of SCC (Nataraj et al, 1997; Wang et al, 1997; Stern et al, 2002) and BCC Stern et al, 2002) from PUVA-treated psoriasis patients in which many mutations bore the UV fingerprint (Fig 2) . They also agree with recent work from our own laboratory that revealed that most Ha-ras mutations detected in PUVAassociated SCC ) and the INK4a-ARF locus (Kreimer-Erlacher et al, 2003) also bore the UV fingerprint. In most previous DNA sequencing studies of genes in human PUVA-associated skin cancers (Wang et al, 1997; Kreimer-Erlacher et al, 2001 Stern et al, 2002) , mutations classified as PUVA type were in the minority. In fact, only one study so far has reported that PUVA-type mutations outnumbered UV-type mutations in human skin cancers (at the p53 gene) (Nataraj et al, 1997) ; however, the authors later acknowledged that they mistakenly classified some mutations at 5 0 -CpT sites as PUVA type and so may have overestimated the presence of PUVA-type mutations (Stern et al, 2002) , Moreover, in a study of mutations at the INK4a-ARF locus in PUVAassociated SCC, no single mutation could be unambiguously classified as PUVA induced (Kreimer-Erlacher et al, 2003) .
A number of potential explanations for the high frequency of UV fingerprint mutations in PUVA-associated tumors have already been proposed (Nataraj et al, 1997; Wang et al, 1997; Kreimer-Erlacher et al, 2001 Seidl et al, 2001; Stern et al, 2002) . One of these is environmental and/ or therapeutic UV exposure. At first glance, our results seem to support this explanation as (1) six of eight patients in this study whose PUVA keratoses harbored UV-specific missense mutations at p53 and/or Ha-ras had a history of therapeutic UVB exposure, and (2) several of the PUVA keratoses we examined were taken from body sites regularly exposed to natural sunlight (Table I) . Moreover, as the comparison of p53 mutational spectra in PUVA keratoses from this study and actinic keratoses from the general population revealed no significant difference in the distribution of UV-type mutations (Fig 1) , it is reasonable to assume that the main initial, causative factor for both types of lesions is UV exposure. When one compares our results with those of previous studies in PUVA-associated SCC, the frequency distributions of UV-and PUVA-type mutations of the p53 gene are similar (Nataraj et al, 1997; Wang et al, 1997; Stern et al, 2002) , whereas those of UV-and PUVAtype mutations of the Ha-ras gene are not . In fact, in this study, there were significantly more UV-type mutations of the Ha-ras gene in PUVA Figure 1 The UV fingerprint dominates the mutation spectra of the p53 gene in PUVA keratoses and actinic keratosis from the general population. p53 mutations detected in actinic keratoses from the general population in several previous studies (for details see Materials and Methods) were pooled and compared with those detected in our collection of PUVA keratoses in terms of type and number. Note that in this study and previous studies a few C ! T transitions occurred at dipyrimidine sites, each opposite a 5 0 -TpG sequence (a potential psoralen-binding site) (see Table III ). In this graph, these mutations are represented in the blank column portions at the top of the column marked C ! T and at the top of the column marked 5 0 -TpG at nondipyrimidine sites. As the origins of these mutations (UV or PUVA) were ambiguous, they were considered separately in the mutational spectrum analysis. Ã When dipyrimidine sites and nondipyrimidine sites were taken together, the proportion of p53 mutations at 5 0 -TpA sites was statistically significantly higher in PUVA keratoses than in actinic keratoses from the general population (nine of 39 (23%) vs one of 56 (2%); Fisher's exact test, p ¼ 0.0012). There were significantly fewer mutations of the ''other'' type in PUVA keratoses than in actinic keratoses (three of 39 (8%) vs 16 of 56 (27%); Fisher's exact test, p ¼ 0.031).
keratoses than in PUVA-associated SCC (Fig 2) . For several reasons, however, we cannot totally rule out the possibility that some of the mutations that we classified as UV type in this study may have been indirectly caused by PUVA exposure. First, it has been reported that stable oxidation products of cytosine and thymidine induced by 8-methoxypsoralen (8-MOP) and UVA or by UVA alone can induce C ! T transitions (Wang et al, 1998) . Second, PUVA is known to generate reactive oxygen species, which in turn may also induce C ! T or CC ! TT transitions (Reid and Loeb, 1993 ). As we have previously stated , however, the hypothesis that exposure to PUVA or UVA alone may result in UV-type mutations is strongly contradicted by results of studies in cell cultures Chiou and Yang, 1995; Gunther et al, 1995) and in mice (Nataraj et al, 1996) in which UV-type mutations were rarely if ever observed after PUVA exposure. Third, fluorescent tubes used for PUVA therapy in Europe emit small portions of radiation within the UVB range, which may in turn cause UV-type mutations (Nataraj et al, 1997) .
Our study also revealed that large percentages of mutation-positive PUVA keratoses harbored two or more mutations in the p53 gene (11 of 16; 69%) or in the Ha-ras gene (five of 11; 45%) (Table IV) . In several specimens, one or more UV-and PUVA-type mutations occurred in both the p53 and the Ha-ras gene. These results are consistent with those of a previous study by Stern et al (2002) , in which 44% of 55 human PUVA-associated nonmelanoma skin cancers (including SCC and BCC) had multiple UV-and/or PUVA-type p53 mutations. Multiple p53 mutations have also been found in murine and human skin cancers and head and neck cancers, and their significance in the context of field cancerization has been previously discussed (Stern et al, 2002 , and references cited therein).
There is broad evidence that alterations in the p53 and Ha-ras gene may cooperate in carcinogenesis in general (for review, see Kreimer-Erlacher et al, 2001) . The fact that in this study p53 mutations and/or Ha-ras mutations were frequently found in PUVA keratoses and that both genes were mutated in more than a quarter of the cases (Table IV) suggest that they also may cooperate in the formation of PUVA keratoses. Greenblatt et al (1994) found that approximately 90% of all p53 mutations in cancers occur between exons 5 and 8 at the hydrophobic region (DNAbinding site) of the p53 gene. In our study, we found that nine of 39 mis-sense/non-sense mutations (23%) occurred in the nonconserved domain of exon 4 (codons 61-89), nine (23%) in the conserved domain III of exon 5 (codons 136-170), eight (21%) in the nonconserved domain of exon 6 (codons 205-220), seven (18%) in the conserved domain IV of exon 7 (codons 226-249), three (8%) in the conserved domain V of exon 8 (codons 281-285), and two (5%) in the nonconserved domain of exon 9 (codons 322 and 323) in the basic C-terminus, which contains the oligomerization 
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domain that is essential in forming the active tetrameric p53 complexes that bind DNA (Table II) . Particularly, mutations in conserved p53 domains have been proposed to abrogate p53 tumor suppressor activity and thereby give the mutation-harboring cells a proliferative growth advantage. The p53 mutations that we found in PUVA keratoses at codon 248 (exon 7) (one C ! T transition) and at codon 281/282 (exon 8) (one C ! T transition and one CC ! TT transition) are well-known hotspots for mutation in skin cancers and frequently in other cancers as well. Although the exact significance of Ha-ras mutations occurring at sites other than the well known codons 12, 13, and 61 is not clear at present (Zarbl et al, 1985; Trahey and McCormick, 1987) , at least some of the Ha-ras mutations that we observed in this study may affect the function of the p21ras protein. For instance, the mutation at codon 8 observed in two PUVA keratoses (C6 and D1) (Table III) has been implicated in guanine nucleotide binding (Lewin et al, 1997) . The replacement of amino acid 13 observed in another PUVA keratosis (A1) is part of the loop 1 region (amino acids 13-17). The replacement of Gly-13 by valine activates the transforming potential of the protein (Pai et al, 1989) . Normally, the b-phosphate group of the bound GDP molecule interacts extensively with residues 13 to 17 of the p21 molecule (Tong et al, 1991) . In our case, Gly-13 was replaced by asparagine. Meanwhile, amino acid changes observed in two other PUVA keratoses (F5 and A1) at positions 62 and 70 concern the switch II region, spanning amino acids 60 to 76. The switch II region undergoes significant structural changes when GTP replaces GDP during the activation of the p21ras protein (Milburn et al, 1990) . In PUVA keratosis F5, Glu-62 was replaced by lysine. Gln-61 and Glu-62 are highly conserved in the small nucleotide binding proteins, and Glu-63 is conserved in all ras gene products, suggesting that the switch II region is important for the function of p21ras proteins (Pai et al, 1990) . Alternatively, however, many Ha-ras mutations found in this study may have occurred as an epiphenomena (without functional relevance) and their formation may have taken place causally unrelated to the formation of PUVA keratoses. For instance, an overall effect of decreased DNA repair capacity, e.g., caused by dysfunction of genes such as p53 (Santamaria et al, 2002) , may have caused at least some of the Ha-ras mutations. This hypothesis is supported by (1) the fact that all but one Ha-ras mutations were found at other sites than the well-known oncogenic hotspots at codons 12, 13, and 61 (Zarbl et al, 1985; Trahey and McCormick, 1987) , and (2) the presence of a high number of silent Ha-ras mutations in the PUVA keratoses. 
Figure 2
Comparison of mutational spectra of PUVA keratoses and PUVAassociated SCC. Pooled data from the literature on p53 (Nataraj et al, 1997; Wang et al, 1997) and Ha-ras (Kreimer-Erlacher et al, 2001) in PUVA-associated SCC were compared with data from this study on p53 and Ha-ras mutations in PUVA keratoses. Regarding the p53 gene, there were no significant differences in any mutation type between PUVA-associated SCC and PUVA keratoses. Regarding the Ha-ras gene, there were significantly fewer UV-type mutations in PUVAassociated SCC than in PUVA keratoses (six of 18 (33%) vs 13 of 18 (72%); Fisher's exact test, p ¼ 0.044); however, there were significantly more mutations of the ''other'' type in PUVA-associated SCC than in PUVA keratoses (seven of 18 (39%) vs 0%; Fisher's exact test, p ¼ 0.007). Mutation types are defined in Table II. An important observation in this study was that most PUVA-type mutations (nine of 13; 69%) at the p53 gene occurred at 5 0 -TpA DNA sequences. For example, three patients (patients B, D, and H) had the same fingerprint mutation at p53, namely a T ! A transversion at a 5 0 -TpA site in exon 6 (codon 220), suggesting that this may be a hotspot codon for PUVA-type mutations. This predominance of mutations at 5 0 -TpA DNA sequences is consistent with results of cell culture studies in which psoralen preferentially bound to 5 0 -TpA sequences and suggests that such sequences are primary targets for PUVA carcinogenesis (Sage 1993; Sage et al, 1993; Yang et al, 1994; Chiou and Yang, 1995) . Also, p53 mutations were found primarily at 5 0 -TpA sequences in SCC induced in mice by chronic topical PUVA treatment (Nataraj et al, 1996) . In this study, however, PUVA-type mutations were also (but less frequently) observed at or opposite 5 0 -TpG sequences on the p53 gene (five mutations) and the Ha-ras gene (two mutations). This finding adds to the knowledge gained from previous mutational studies of p53 (Nataraj et al, 1997; Seidl et al, 2001) , Ha-ras (Kreimer-Erlacher et al, 2001) , and the INK4a-ARF locus (Kreimer-Erlacher et al, 2003) of PUVA-associated skin cancers from psoriasis patients, in which most PUVA-type mutations were observed at 5 0 -TpG sequences. Possible reasons for the frequent occurrence of mutations at 5 0 -TpG sequences in human PUVA-associated skin tumors have been previously discussed in detail (Nataraj et al, 1997; Wang et al, 1997; Kreimer-Erlacher et al, 2001 Seidl et al, 2001) . In brief, some have speculated that the application of too high and, thus, clinically irrelevant UVA doses in PUVA cell culture mutagenesis studies, the different processing of psoralen photoadducts under in vitro conditions, or both might produce mutational spectra different from those seen in human skin cancers.
In this study of PUVA keratoses, a small number of mutations at p53 (two of 39; 5%) could not be classified as either the UV or PUVA type and so were classified as ''other.'' As mentioned earlier and as was the case in this study (Table I) , psoriasis patients often have a history of exposure to other potentially carcinogenic treatment agents, including ionizing radiation, methotrexate, arsenic, and topical tar. One or more of these agents, or perhaps some as yet unidentified agent or agents, may have been responsible for these ''other'' mutations in this study.
Nevertheless, our results demonstrate that p53 and Haras are often mutated in PUVA keratoses and that the resulting mutations may cooperate in the formation of those lesions. Most of the Ha-ras and p53 mutations we observed were of the UV type, which suggests that environmental and/or therapeutic UV exposure may be the major primary causative factor in PUVA keratoses. PUVA itself seems to play a smaller, although direct, role in causing these mutations. As previously suggested (Kreimer-Erlacher et al, 2003) , however, it may be that it is through nonmutational effects such as PUVA-induced tumor promotion and immunosuppression (Strauss et al, 1980; Kripke et al, 1982) rather than direct mutagenic effects that PUVA promotes skin carcinogenesis after long-term treatment with high cumulative UVA doses. Moreover, PUVA-induced apoptosis (Santamaria et al, 2002) in normal keratinocytes and the lack of apoptosis in p53 mutants cells may also have the capacity to promote strongly the development of PUVA keratoses and subsequent SCC. Indeed, the similar mutational spectra of PUVA-associated SCC and PUVA keratoses indirectly suggest that PUVA keratoses may be precursors of at least some SCC. A quarter of our PUVA keratoses showed no mutation in either the p53 or Ha-ras gene. This observation raises the possibility that these lesions, if not mutated in other key cancer genes, for instance such as INK4a-ARF locus (Kreimer-Erlacher et al, 2003) , may have no capacity to progress towards a malignant tumor type.
Materials and Methods
Patients and tumors Twenty-eight squamous keratoses from 10 PUVA-treated psoriasis patients (four females and six males) were available for DNA mutational analysis. All 28 were randomly selected from an archive of paraffin-embedded lesions previously identified and removed in a PUVA follow-up study at the Department of Dermatology of the Karl-Franzens-University (Graz, Austria) (Schö llnast, 1997). All of the selected lesions bore the clinical and histologic features of PUVA keratosis previously described by Van Praag et al (1993) . The patients' demographics, tumor characteristics, and PUVA treatment data are shown in Table I . According to Australian law, no IRB approval was necessary specifically for the study at the time when the study was performed.
DNA extraction DNA was extracted from the 28 lesions as follows. First, the paraffin-embedded samples were macrodissected or microdissected or both in order to (1) eliminate nonlesional tissue adjacent to the PUVA keratoses, and (2) obtain normal tissue from each sample for control polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) and sequencing studies. Tissues were then sectioned into 7 to 10 mm thick slices and placed on SuperFrost Plus slides (Menzel, Braunschweig, Germany), deparaffinized with xylene for 10 min and ethanol for 10 min, air dried, and dampened in deionized water. Next, tissues were scraped off the slides, suspended in 50 to 100 mL of a solution containing 0.1 M Tris-HCl (pH 8.0) and 1 mg proteinase K per mL, incubated at 551C overnight, boiled for 10 min, and finally stored at À201C until analysis.
PCR-SSCP analysis Once extracted, the lesional DNA was subjected to PCR-SSCP as follows. Oligonucleotide primers for Ha-ras exons 1 and 2 and exons 3 and 4 and for p53 exons 4 to 9 were used in PCR reactions, as previously described Seidl et al, 2001) . The template for PCR consisted of 4 mL of DNA lysate in a 50 mL solution containing 10 mM Tris-HCl, pH 8.3; 50 mM KCl; 1.5 mM MgCl 2 (for PCR involving Ha-ras exons 1 and 2 and p53 exons 4-9) or 1 mM MgCl 2 (for PCR involving Ha-ras exons 3 and 4); 200 mM of each deoxyribonucleoside triphosphate; 10 pM of the upstream primer; 10 pM of the downstream primer; and 2.5 U of AmpliTaq Gold Polymerase (Perkin Elmer, Vienna, Austria). Reaction mixtures were subjected to 40 cycles of amplification in a Perkin Elmer Thermocycler Model 9700 (Perkin Elmer, Foster City, California). Each cycle consisted of denaturation at 941C for 45 s; annealing at 581C (Ha-ras exons 1 and 2), 551C (Ha-ras exons 3 and 4), or 601C (p53 exons 4-9) for 30 s; and polymerization at 721C for 30 s. Before the first cycle, tubes containing PCR mixtures were incubated for 12 min at 941C; after the last cycle, for 7 min at 721C. Tubes without template DNA were included in each PCR run as negative controls for potential contamination of PCR reactions. For SSCP analysis, PCR products were purified by gel electrophoresis on 3% Metaphor agarose gels (BioWhittaker Molecular Applications, Rockland, Maine) and subsequent gel extraction (Qiagen, Hilden, Germany). Samples were then applied to a commercially available gel (GeneGel Excel 12.5 cm/24 slots; Pharmacia Biotech, Uppsala, Sweden) and run for 1 h, 30 min at 51C (for Ha-ras exons 1 and 3), 101C (for p53 exons 7-9), 151C (for Ha-ras exon 2 and p53 exon 6), or 201C (for Ha-ras exon 4 and p53 exons 4 and 5). The running conditions were as follows: voltage, 600 V; current, 25 mA; power, 15 W. Finally, the gels were stained using a DNA silver staining kit (Pharmacia Biotech). PCR-SSCP was performed at least twice per sample.
Direct sequencing Each DNA sample shown by PCR-SSCP analysis to contain aberrant (i.e., mutated) bands was then subjected to direct sequencing of its DNA. In brief, 60 ng of each tumor's DNA was amplified with 3.2 pM of primer (PE Applied Biosystems, Weiterstadt, Germany). The amplified products were then precipitated and analyzed on an ABI Prism 310 system (Perkin Elmer). Human placental DNA was simultaneously analyzed to rule out PCR-generated mutations. Sequencing analysis was performed at least twice per sample, and the presence of a mutation or base change was always confirmed by sequencing the opposite DNA strand.
Comparisons of mutational spectra and mutation types The p53 mutational spectrum of our collection of PUVA keratoses was compared with the p53 mutational spectrum derived from a pool of previous sequencing studies of actinic keratoses from the general population (Nelson et al, 1994; Taguchi et al, 1994; Ziegler et al, 1994; Park et al, 1996) . No such comparison was made for Ha-ras because we were unable to find any applicable published data via a search of PubMed (www.ncbi.nlm.nih.gov). In addition, however, the p53 and Ha-ras mutational spectra of our collection of PUVA keratoses were compared with those derived from previous sequencing studies of SCC from PUVA-treated psoriasis patients (Nataraj et al, 1997; Wang et al, 1997; Kreimer-Erlacher et al, 2001) . The type, number, and frequency of mutations observed in our collection of PUVA keratoses (classified by origin as UV, PUVA, UV/ PUVA, or other) were compared with the type, number, and frequency of mutations in actinic keratoses from the general population or SCC from PUVA-treated psoriasis patients.
Statistical analysis
Differences between groups of subjects and lesions in terms of type and number of mutations were analyzed for statistical significance using Fisher's exact test or the w 2 test in the StatView statistical analysis program version 5.0.1 (SAS Institute Inc., Cary, North Carolina). p 0.05 was considered statistically significant.
